Intensifying Competition and Clinical Trial Delay Risk in the Acute Ischemic Stroke Market for TMS-007

This theme concerns the risk that TMS-007’s competitive advantage may erode and its clinical trials may be delayed or discontinued due to competing candidates such as Tenecteplase, Sovateltide, LT3001 and biosimilars, as well as stalled patient enrollment and decisions by potential partners.